<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606461</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-020</org_study_id>
    <secondary_id>2015-003594-14</secondary_id>
    <nct_id>NCT02606461</nct_id>
  </id_info>
  <brief_title>Selinexor in Advanced Liposarcoma</brief_title>
  <acronym>SEAL</acronym>
  <official_title>A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of
      patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279
      total patients will be randomized to study treatment (selinexor or placebo).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Phase 2 portion of the study, 57 patients were randomized to selinexor (60 mg) or
      placebo at a 1:1 allocation ratio.

      In the Phase 3 portion of the study, approximately 222 patients will be randomized to
      selinexor (60 mg) or placebo with a 2:1 allocation ratio.

      Patients who progress during the blinded portion of the study will be unblinded and if
      receiving:

        -  placebo, may cross over to open-label selinexor (60mg twice weekly)

        -  selinexor, will be withdrawn from further treatment and followed for survival

      Study treatment will be given twice weekly on Day 1 and Day 3 during Weeks 1-6 of each
      six-week (42 day) cycle until disease progression or intolerability.

      Treatment will continue until one or more of the following occurs:

        -  Disease progression, as defined by RECIST v1.1 Response Criteria

        -  Clinical progression, as determined by the treating physician

        -  Unacceptable AEs or failure to tolerate study treatment

        -  Patient withdrawal

        -  Patient discontinuation due to non-compliance
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess and compare Progression-free Survival (PFS) of patients with advanced unresectable DDLS treated with selinexor (60 milligrams [mg]) or placebo.</measure>
    <time_frame>From the date of randomization until the first date of disease progression, per RECIST v1.1 Response Criteria, or death due to any cause; up to approximately 30 months.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">279</enrollment>
  <condition>Dedifferentiated Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Selinexor 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: 57 patients were randomized to selinexor or placebo in a 1:1allocation.
Phase 3: Approximately 222 patients will be randomized to selinexor (~148 patients) or placebo (~74 patients) in a 2:1 allocation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 2: Approximately 57 patients were randomized to selinexor or placebo in a 1:1 allocation.
Phase 3: Approximately 222 patients will be randomized to selinexor (~148 patients) or placebo (~74 patients) in a 2:1 allocation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor 60mg</description>
    <arm_group_label>Selinexor 60mg</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥12 years of age

          2. Body surface area (BSA) ≥ 1.2 m2

          3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
             DDLS requiring treatment

          4. Must have measurable disease per RECIST v1.1 Response Criteria

          5. Radiologic evidence of disease progression within 6 months prior to randomization. If
             the patient received other intervening therapy after documented disease progression,
             further disease progression must be documented after the completion of the intervening
             therapy

          6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
             exceed 5 prior lines)

          7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
             days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
             with all clinically significant therapy- related toxicities having resolved to less
             than or equal to Grade 1

        Exclusion Criteria:

          1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

          2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
             (HIV) infection.

          3. Known central nervous system metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, M.D., Ph.D.</last_name>
    <email>Mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Chmielowski, MD</last_name>
      <email>BChmielowski@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Bartosz Chmielowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sant Chawla, MD</last_name>
      <phone>310-552-9999</phone>
      <email>santchawla@sarcomaoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sant Chawla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Ganjoo, MD</last_name>
      <email>kganjoo@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Ganjoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado-Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Villalobos, MD, PhD</last_name>
      <phone>720-848-0467</phone>
      <email>Victor.M.Villalobos@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Villalobos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Attia, DO</last_name>
      <phone>904-953-7290</phone>
      <email>Attia.Steven@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Attia, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Agulnik, FRCPC, MD</last_name>
      <email>Mark.Agulnik@nm.org</email>
    </contact>
    <investigator>
      <last_name>Mark Agulnik, FRCPC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Meyer, MD</last_name>
      <phone>410-955-8893</phone>
      <email>cmeyer12@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin Choy, MD, PhD</last_name>
      <phone>617-724-4000</phone>
      <email>echoy@partners.org</email>
    </contact>
    <investigator>
      <last_name>Edwin Choy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hohos, RM</last_name>
      <phone>617-582-7162</phone>
      <email>mhohos@partners.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Wagner, MM, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Schuetze, MD</last_name>
      <email>scotschu@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Schuetze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Olsen</last_name>
      <phone>507-266-5027</phone>
      <email>okuno.scott@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Okuno, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washingron University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Van Tine, MD, PhD</last_name>
      <phone>314-362-7997</phone>
      <email>bvantine@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Van Tine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Schwartz, MD</last_name>
      <phone>646-317-6041</phone>
      <email>gks2123@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrinal Gounder Gounder, MD</last_name>
      <phone>646-888-4167</phone>
      <email>gounderm@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Mrinal Gounder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Institute of Cancer</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Riedel, M.D.</last_name>
      <phone>919-681-1883</phone>
      <email>richard.riedel@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Colleen Piechocki, RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Richard Riedel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cancer Center, Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Chen, MD</last_name>
      <phone>614-685-9754</phone>
      <email>james.chen@OSUmc.edu</email>
    </contact>
    <investigator>
      <last_name>James Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Ryan, MD</last_name>
      <email>ryanc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Hartner, MD</last_name>
      <email>Lee.Hartner@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lee Hartner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Burgess, MD</last_name>
      <phone>412-692-4724</phone>
      <email>burgessma@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa Burgess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeta Somaiah, MD</last_name>
      <phone>713-563-5056</phone>
      <email>nsomaiah@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Neeta Somaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Pollack, MD</last_name>
      <phone>520-609-0301</phone>
      <email>lcranmer@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Seth Pollack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shailendra Verma, MD</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70179</phone_ext>
      <email>sverma@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Shailendra Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albiruni Razak, MD</last_name>
      <phone>1 (647) 970 9845</phone>
      <email>albiruni.razak@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Albiruni Razak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced unresectable dedifferentiated liposarcoma</keyword>
  <keyword>selinexor</keyword>
  <keyword>KCP-330</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>Phase 2 / 3</keyword>
  <keyword>dedifferentiated liposarcoma</keyword>
  <keyword>liposarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

